Mizuho lowered the firm’s price target on Inspire Medical (INSP) to $85 from $130 and keeps an Outperform rating on the shares. The firm says the big news out of the company’s Q4 update was the “steep” guidance reduction.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical downgraded to Hold from Buy at Nephron Research
- Inspire Medical downgraded to Equal Weight from Overweight at Wells Fargo
- Inspire Medical downgraded to Neutral from Outperform at Baird
- Closing Bell Movers: Cisco falls 7% after earnings
- Inspire Medical Updates Governance, Outlines 2026 Growth Outlook